FIELD: pharmaceuticals.
SUBSTANCE: compound of Formula (I), where the values of R1-R3, X, Y are defined in the claims, and its pharmaceutically acceptable salts. The compounds are inhibitors of ataxia-telangiectasia and RAD-3-related protein kinase (ATR). Also disclosed are pharmaceutical compositions containing a compound of Formula (I) or pharmaceutically acceptable salts thereof.
EFFECT: compounds can be used to treat cancers that depend on ATR kinase activity.
37 cl, 3 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRAZOLOPYRIMIDINE COMPOUNDS AS ADENOSINE RECEPTOR ANTAGONISTS | 2019 |
|
RU2806758C2 |
| COMPOUND OF FORMULA (I), PHARMACEUTICAL COMPOSITION, APPLICATION OF COMPOUND OF FORMULA (I) FOR TREATMENT OF HEMATOLOGICAL AND/OR PROLIFERATIVE DISORDERS | 2016 |
|
RU2758259C2 |
| PYRAZOLO[3,4-b]PYRIDINE COMPOUNDS AS TAM AND MET KINASE INHIBITORS | 2019 |
|
RU2773611C1 |
| HETEROCYCLIC MAT2A INHIBITORS AND METHODS OF THEIR USE FOR CANCER TREATMENT | 2019 |
|
RU2809987C2 |
| BICYCLIC AMINE DERIVATIVES AS TYROSINE KINASE INHIBITORS | 2007 |
|
RU2465275C2 |
| UREA-BASED COMPOUNDS AND COMPOSITIONS BASED ON THEM AS SMARCA2/BRM ATPASE INHIBITORS | 2019 |
|
RU2798462C2 |
| 3-(1-OXOISOINDOLIN-2-YL)PIPERIDINE-2,6-DIONE DERIVATIVES AND VARIANTS OF THEIR USE | 2018 |
|
RU2795850C2 |
| PHARMACOLOGICALLY ACTIVE COMPOUNDS AS INHIBITORS OF THE TAM FAMILY RECEPTOR TYROSINE KINASE | 2016 |
|
RU2750727C2 |
| TYROSINE KINASE INHIBITORS | 2006 |
|
RU2408584C2 |
| NOVEL COMPOUNDS THAT ARE ERK INHIBITORS | 2013 |
|
RU2660429C2 |
